Fresenius Se & Co. Kgaa · XETR:FRE

Fresenius Se & Co. Kgaa — Fresenius — Dresdner Kleinwort German Investment Seminar 2008

29 slides from Fresenius Se & Co. Kgaa's conference presentation, January 2008

  1. Slide 1: Dresdner Kleinwort German Investment Seminar

    Dresdner Kleinwort German Investment Seminar January 14 - 16, 2008

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive

  3. Slide 3: Achieving Profitable Growth in Attractive Health Care Segments

    Achieving Profitable Growth in Attractive Health Care Segments Fresenius Biotech Oncology and Immunology Therapies Fresenius Fresenius Fresenius Fresenius Medical Care Kabi HELIOS VAMED Dialysis Equipment Infusion and Nutrition Hospital Operations Engineering and and Services Therapies Services for

  4. Slide 4: Fresenius Group: Excellent Sales and Earnings Growth Track Record

    Fresenius Group: Excellent Sales and Earnings Growth Track Record Sales EBIT in €m 10,777 in €m 1,444 1,184 % % 8,390 12 16 GR GR CA CA 3,812 +11% cc2) +17% cc3) 377 19971 2006 Q1-3 2007 19971 2006 Q1-3 2007 1) German GAAP 2) at actual rates: +7 % 3) at actual rates: +12 % Dresdner Kleinwort German

  5. Slide 5: Fresenius Group: Poised for Continued Profitable Growth

    Fresenius Group: Poised for Continued Profitable Growth - Leading positions in non-cyclical markets with predictable growth - Industry-leading organic growth in all business segments - Diversified revenue and earnings base - International expansion as key organic growth driver - Negligible currency

  6. Slide 6: Fresenius Kabi

    Fresenius Kabi Untertitel der Kapiteltrennseite Maximal zweizeilig, 18 pt Dresdner Kleinwort German Investment Seminar, Fresenius SE, Investor Relations © Copyright, January 2008 Page 6

  7. Slide 7: Fresenius Kabi: Leading Market Positions in Infusion Therapy and Clinical Nutrition

    Fresenius Kabi: Leading Market Positions in Infusion Therapy and Clinical Nutrition - Focus on organic growth and Global production and selective acquisitions distribution network - Significant growth in emerging markets 5-years sales CAGR (2006) - Asia-Pacific: 21 % cc - Latin America: 15 % cc - St

  8. Slide 8: Fresenius Kabi: Sales and Earnings Development

    Fresenius Kabi: Sales and Earnings Development Sales EBIT % 1,893 in €m 7 in €m C AGR 291 1,441 1,494 242 % +6 % 32 +14 % GR CA 97 2002 2006 Q1-3 2007 2002 2006 Q1-3 2007 Dresdner Kleinwort German Investment Seminar, Fresenius SE, Investor Relations © Copyright, January 2008 Page 8

  9. Slide 9: Fresenius Kabi: Recent M&A Activity

    Fresenius Kabi: Recent M&A Activity Strengthen the fast-growing Clinical Nutrition segment: - Acquisition of Nestlé’s enteral nutrition businesses in France and in Spain Grow attractive I.V. drug segment: - Acquisition of Ribbon – a leading European manufacturer of antibiotic agents Expand infusion

  10. Slide 10: Fresenius Kabi: 2007 Financial Outlook Fully Confirmed

    Fresenius Kabi: 2007 Financial Outlook Fully Confirmed Guidance Organic revenue 6–8% growth EBIT margin 16.0 – 16.5 % Dresdner Kleinwort German Investment Seminar, Fresenius SE, Investor Relations © Copyright, January 2008 Page 10

  11. Slide 11: Fresenius Helios / Fresenius Vamed

    Fresenius Helios / Fresenius Vamed Dresdner Kleinwort German Investment Seminar, Fresenius SE, Investor Relations © Copyright, January 2008 Page 11

  12. Slide 12: Fresenius Helios / Fresenius Vamed: Sales and Earnings Development

    Fresenius Helios / Fresenius Vamed*: Sales and Earnings Development Sales EBIT in €m in €m 2,155 154 % 122 1,601 32 % 59 GR CA GR CA +5 % +16 % 701 24 2002 2006 Q1-3 2007 2002 2006 Q1-3 2007 * Formerly known as Fresenius ProServe business segment Dresdner Kleinwort German Investment Seminar, Freseni

  13. Slide 13: Fresenius Helios: Top-Tier Private Hospital Operator in Germany

    Fresenius Helios: Top-Tier Private Hospital Operator in Germany - Germany is Europe’s largest hospital market (> € 60 bn market size) - Only 11 % of German acute hospital beds managed by private operators - Significant German hospital privatization opportunity - Fresenius Helios has a strong track r

  14. Slide 14: Fresenius Vamed: Engineering and Services for Hospitals and Health Care Facilities

    Fresenius Vamed: Engineering and Services for Hospitals and Health Care Facilities - Specialized in hospital services – from project development to International Network hospital management - 430 hospital development projects in 47 countries - Management services in 105 hospitals with >30,000 beds -

  15. Slide 15: Fresenius Helios / Fresenius Vamed: 2007 Earnings Outlook Raised

    Fresenius Helios / Fresenius Vamed*: 2007 Earnings Outlook Raised Guidance Organic 2–3% revenue growth EBIT Raised > € 170 m * Formerly known as Fresenius ProServe business segment Dresdner Kleinwort German Investment Seminar, Fresenius SE, Investor Relations © Copyright, January 2008 Page 15

  16. Slide 16: Fresenius Biotech

    Fresenius Biotech Dresdner Kleinwort German Investment Seminar, Fresenius SE, Investor Relations © Copyright, January 2008 Page 16

  17. Slide 17: Fresenius Biotech: Attractive Growth Option Based on Proprietary Antibody Technology

    Fresenius Biotech: Attractive Growth Option Based on Proprietary Antibody Technology - Malignant ascites dossier dispatched to EMEA end of 2007 – as planned - Removab® partnering process for North America and Japan ongoing - 2007 EBIT outlook of ~ € -50 m confirmed Dresdner Kleinwort German Investme

  18. Slide 18: Fresenius Group: Earnings Outlook 2007 Raised

    Fresenius Group: Earnings Outlook 2007 Raised 2007 outlook Guidance Adjusted to Revenue growth upper end of 9 – 10 % in constant currency range Net income growth in constant currency Raised >25 % Mid-term outlook 15/15 by 2010 Revenue/EBIT margin Revenue of € 15 bn, EBIT margin of 15 % Dresdner Klei

  19. Slide 19: Attachments

    Attachments Untertitel der Kapiteltrennseite Maximal zweizeilig, 18 pt Dresdner Kleinwort German Investment Seminar, Fresenius SE, Investor Relations © Copyright, January 2008 Page 19

  20. Slide 20: Fresenius Group: Profit and Loss Statement

    Fresenius Group: Profit and Loss Statement €m Q3/ Q1-3/ Q1-3/2007 YoY Remarks 2007 2007 actual constant Q1-3/2007 rates rates Sales 2,798 8,390 +7 % +11 % EBIT 404 1,184 +12 % +17 % 86 % of debt in Interest result -94 -279 +5 % 0% fixed/hedged rates Taxes -112 -326 -4 % -10 % 36.0 % tax rate Net inc

  21. Slide 21: Fresenius Group: Cash Flow

    Fresenius Group: Cash Flow €m Q3/2007 Q1-3/2007 Q1-3/2007 YoY Cash flow 310 892 +19 % Change in Working capital +49 +20 +114 % Operating Cash flow 359 912 +55 % Capex (net) -168 -465 -29 % Cash flow 191 447 +96 % (before acquisitions and dividends) Acquisitions (net) -20 -182 +94 % Dividends -3 -191

  22. Slide 22: Fresenius Group: Debt and Interest Ratios

    Fresenius Group: Debt and Interest Ratios Sept 30, Dec 31, Net debt/EBITDA 2007 2006 3.6 3.5 3.3 Debt (€m) 5,596 5,872 3.4 3.2 3.2 3.2 3.0 3.0 Net debt (€m) 5,277 5,611 3.0 2.9 2.8 2.8 2.7 2.7 Net debt/EBITDA 2.7 3.0 * 2.6 2.4 EBITDA/Interest 5.3 4.6 * 2.2 2.3 2.2 2.0 1.8 * excl. gain and EBITDA fro

  23. Slide 23: Fresenius Group: Double-Digit EBIT Growth in all Business Segments

    Fresenius Group: Double-Digit EBIT Growth in all Business Segments Fresenius Fresenius Fresenius Q1-3/2007 Medical Care Kabi ProServe Sales US$ 7,151 m € 1,494 m € 1,601 m Growth +16 % +6 % +5 % EBIT US$ 1,152 m € 242 m € 122 m Growth +19 % +14 % +16 % Dresdner Kleinwort German Investment Seminar, F

  24. Slide 24: Fresenius Kabi: Strong Sales Growth in Q3/2007 – Fully in Line with Guidance

    Fresenius Kabi: Strong Sales Growth in Q3/2007 – Fully in Line with Guidance Organic €m Q1–3/2007 Q1-3/2006 Growth Total Sales 1,494 1,404 7% By Product Segment: Infusion Therapy 793 761 5% Clinical Nutrition 610 555 11 % Transfusion Technology 91 88 4% Dresdner Kleinwort German Investment Seminar,

  25. Slide 25: Fresenius Kabi: Sales Growth by Region

    Fresenius Kabi: Sales Growth by Region Regional Sales Q1-3/ Q1-3/ Growth Organic €m 2007 2006 Growth Germany 322 319 1% 1% Europe ex Germany 684 650 5% 5% Asia-Pacific 227 190 19 % 22 % Latin America 105 94 12 % 10 % RoW 156 151 3% 10 % Total sales 1,494 1,404 6% 7% Dresdner Kleinwort German Investm

  26. Slide 26: Fresenius Kabi: 100 bps EBIT Margin Improvement Compared to Q1-3/2006

    Fresenius Kabi: 100 bps EBIT Margin Improvement Compared to Q1-3/2006 €m Q1-3/2007 Q1-3/2006 Change EBIT 242 213 14 % EBIT margin 16.2 % 15.2 % EBIT by Region: Europe 215 187 15 % EBIT margin 21.4 % 19.3 % International 81 72 13 % EBIT margin 16.6 % 16.6 % Corporate and Corporate R&D -54 -46 17 % Ne

  27. Slide 27: Fresenius Helios / Fresenius Vamed: On Track to Achieve 2007 Sales Guidance

    Fresenius Helios / Fresenius Vamed: On Track to Achieve 2007 Sales Guidance €m Q1-3/2007 Q1-3/2006 Change Organic Sales 1,601 1,526 5% 1% Sales by Division: Hospital Operations (Helios) 1,348 1,204 12 % 3% Engineering + Services for 253 322* -21 % -7 % hospitals (Vamed + Pharmatec) Order intake Engi

  28. Slide 28: Fresenius Helios / Fresenius Vamed: 70 bps EBIT Margin Improvement Compared to Q1-3/2006

    Fresenius Helios / Fresenius Vamed: 70 bps EBIT Margin Improvement Compared to Q1-3/2006 €m Q1-3/2007 Q1-3/2006 Change EBIT 122 105 16 % EBIT margin 7.6 % 6.9 % EBIT by Division: Hospital Operations 111 94 18 % EBIT margin 8.2 % 7.8 % Engineering + Services for hospitals 13 14* -7 % EBIT margin 5.1

  29. Slide 29: Financial Calendar

    Financial Calendar 20.2.2008 Report on Fiscal Year 2007 30.4.2008 Report on 1st quarter 2008 21.5.2008 Annual General Meeting, Frankfurt/Main 30.7.2008 Report on 1st half 2008 4.11.2008 Report on 1st-3rd quarters 2008 Contact Birgit Grund SVP Investor Relations Fresenius SE Telephone: +49 6172 608-2

Fresenius — Dresdner Kleinwort German Investment Seminar 2008 on 6ix